Using SIFT and PolyPhen to Predict Loss-of-function and Gain-of-function Mutations
Overview
Molecular Biology
Affiliations
Context: The interpretation of novel missense variants is a challenge with increasing numbers of such variants being identified and a responsibility to report the findings in the context of all available scientific evidence. Various in silico bioinformatic tools have been developed that predict the likely pathogenicity of missense variants; however, their utility within the diagnostic setting requires further investigation.
Aim: The aim of our study was to test the predictive value of two of these tools, sorting intolerant from tolerant (SIFT) and polymorphism phenotyping (PolyPhen), in a set of 141 missense variants (131 pathogenic, 8 benign) identified in the ABCC8, GCK, and KCNJ11 genes.
Methods: Sixty-six of the mutations caused a gain of protein function, while 67 were loss-of-function mutations. The evolutionary conservation at each residue was also investigated using multiple sequence alignments from the UCSC genome browser.
Results: The sensitivity of SIFT and PolyPhen was reasonably high (69% and 68%, respectively), but their specificity was low (13% and 16%). Both programs were significantly better at predicting loss-of-function mutations than gain-of-function mutations (SIFT, p = 0.001; PolyPhen, p < or = 0.0001). The most reliable method for assessing the likely pathogenicity of a missense variant was to investigate the degree of conservation at the affected residue. Eighty-eight percent of the mutations affected highly conserved residues, while all of the benign variants occurred at residues that were polymorphic across multiple species.
Conclusions: Although SIFT and PolyPhen may be useful in prioritizing changes that are likely to cause a loss of protein function, their low specificity means that their predictions should be interpreted with caution and further evidence to support/refute pathogenicity should be sought before reporting novel missense changes.
Lemberger U, Ernhofer B, Krieger S, Bruchbacher A, Oszwald A, Laukhtina E Eur Urol Open Sci. 2024; 71:38-48.
PMID: 39717660 PMC: 11664179. DOI: 10.1016/j.euros.2024.10.022.
Zhao T, Dong X, Zhao T, Han Z Am J Transl Res. 2024; 16(10):5990-6007.
PMID: 39544793 PMC: 11558429. DOI: 10.62347/XNGV7396.
New ABL1 Kinase Domain Mutations in BCR::ABL1-Positive Acute Lymphoblastic Leukemia.
Li Z, Peng D, Deng J, Xiong L, Yin P, Hu J Cancer Med. 2024; 13(20):e70317.
PMID: 39440695 PMC: 11497109. DOI: 10.1002/cam4.70317.
Abida , Alzahrani A, Alhuthali H, Alkathiri A, Almaghrabi R, Alshehri J Med Oncol. 2024; 41(11):290.
PMID: 39420072 DOI: 10.1007/s12032-024-02532-0.
Gusakova M, Dzhumaniiazova I, Zelenova E, Kashtanova D, Ivanov M, Mamchur A Front Oncol. 2024; 14:1420176.
PMID: 39301547 PMC: 11410565. DOI: 10.3389/fonc.2024.1420176.